Blood Cell Ratios as Predictors of Response to Platelet-Rich Plasma in Knee Osteoarthritis
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 60 years old?
Source: NCT07617233, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Utku Gürhan
- Trial code
- NCT07617233
- Record updated
- 23 June 2026
- Original description
Intra-articular platelet-rich plasma (PRP) injection is a widely used treatment for knee osteoarthritis, but patients respond to it very differently and there is currently no simple, inexpensive way to predict who will benefit. The neutrophil-to-lymphocyte ratio (NLR) and related indices derived from a routine complete blood count reflect a person's baseline inflammatory state. This prospective single-arm observational cohort study investigates whether the baseline NLR, together with the platelet-to-lymphocyte ratio (PLR), the systemic immune-inflammation index (SII), and the monocyte-to-lymphocyte ratio (MLR), predicts the clinical response to intra-articular PRP in patients with Kellgren-Lawrence grade 2 to 3 knee osteoarthritis. The investigators will enroll 120 patients aged 40 to 60 years, each of whom receives a standardized course of three leukocyte-poor PRP injections one week apart. Patients are followed for 6 months, and the primary clinical outcome is the change in the WOMAC osteoarthritis index at 6 months. Outcome assessors are blinded to patients' blood-count values. If a baseline blood ratio predicts response, it could become a low-cost tool to guide patient selection for PRP.Read full original descriptionShow less
Baseline Neutrophil-to-Lymphocyte Ratio and Related Complete Blood Count-Derived Inflammatory Indices as Predictors of Clinical Response to Intra-Articular Platelet-Rich Plasma in Knee Osteoarthritis: A Prospective Single-Arm Cohort Study
Intra-articular platelet-rich plasma (PRP) injection is a widely used treatment for knee osteoarthritis, but patients respond to it very differently and there is currently no simple, inexpensive way to predict who will benefit. The neutrophil-to-lymphocyte ratio (NLR) and related indices derived from a routine complete blood count reflect a person's baseline inflammatory state. This prospective single-arm observational cohort study investigates whether the baseline NLR, together with the platelet-to-lymphocyte ratio (PLR), the systemic immune-inflammation index (SII), and the monocyte-to-lymphocyte ratio (MLR), predicts the clinical response to intra-articular PRP in patients with Kellgren-Lawrence grade 2 to 3 knee osteoarthritis. The investigators will enroll 120 patients aged 40 to 60 years, each of whom receives a standardized course of three leukocyte-poor PRP injections one week apart. Patients are followed for 6 months, and the primary clinical outcome is the change in the WOMAC osteoarthritis index at 6 months. Outcome assessors are blinded to patients' blood-count values. If a baseline blood ratio predicts response, it could become a low-cost tool to guide patient selection for PRP.
Inclusion: Age 40 to 60 years; Symptomatic primary knee osteoarthritis, Kellgren-Lawrence grade 2 or 3 on weight-bearing radiographs; Body mass index below 40; Candidate for and scheduled to receive a course of intra-articular platelet-rich plasma for the index knee; Able and willing to provide written informed consent and to attend the 6-month follow-up schedule.
Exclusion: Current anticoagulant or antiplatelet therapy, or current or recent chemotherapy; Intra-articular injection of the index knee within the previous 6 months; Systemic inflammatory or autoimmune disease; Active acute infection at the time of enrollment; Any contraindication to platelet-rich plasma per the 2025 GRIIP recommendations; Inability to comply with the planned follow-up schedule.